Printer Friendly

LATEST DATA PRESENTED ON RECENTLY APPROVED CORONARY LASER ANGIOPLASTY DEVICE AT AMERICAN COLLEGE OF CARDIOLOGY MEETING

LATEST DATA PRESENTED ON RECENTLY APPROVED CORONARY LASER ANGIOPLASTY
 DEVICE AT AMERICAN COLLEGE OF CARDIOLOGY MEETING
 Laser Device Improves Success Rates and Decreases
 Complications for Patients with Complex Heart Disease
 DALLAS, April 15 /PRNewswire/ -- Interventional cardiologists utilizing a laser device to treat patients with heart disease report high success rates in data presented at the 41st Annual Scientific Session of the American College of Cardiology (ACC) in Dallas, despite a trend toward more complex blockages.
 According to Robert E. Wall, chairman and chief executive officer of Irvine, Calif.-based Advanced Interventional Systems (NASDAQ: LAIS), the advent of excimer laser coronary angioplasty (ELCA), pioneered by LAIS, significantly changes the way cardiologists treat patients with blocked arteries in the heart.
 "Utilizing laser angioplasty, interventional cardiologists are able to treat more complex disease, such as blockages longer than 20 millimeters, with a higher probability of success and with lower complication rates," Wall said.
 "Published data shows that success rates decline and the occurrence of major complications increase when balloons are used alone to treat more complex cases of heart disease," he said.
 Conventional balloon angioplasty remodels plaque rather than removing it. In comparison, laser angioplasty opens clogged arteries in the heart by vaporizing the plaque causing the blockage.
 "Eighty percent of the patients included in a prospective study reported on at the ACC, today, had highly complex blockages. Even so, the success rate remained high -- at approximately 90 percent -- with a significantly low rate of major complications. If laser angioplasty had not been available as a treatment alternative, many of these patients would have gone to bypass surgery," Wall said.
 The Dymer 200+ system used in these laser angioplasty procedures is the first laser for clearing clogged arteries in the heart to receive approval from the federal Food and Drug Administration.
 "Laser angioplasty makes it possible for patients with complex cases of heart disease to be treated with a procedure that is not only less physically traumatic than bypass surgery but also less costly," Wall said.
 Cardiovascular disease is the leading cause of death in the United States, accounting for approximately 1 million, or 50 percent of all deaths annually. An estimated 560,000 patients worldwide undergo balloon angioplasty each year, while nearly 590,000 patients wotional devices such as laser angioplasty.
 Advanced Interventional Systems pioneered excimer laser coronary angioplasty and is the technological leader in the development of laser systems for cardiovascular applications. The company was founded in 1986. In November 1991, Advanced Interventional Systems completed its initial public offering, and on Jan. 31, 1992, it received the first and only approval, to date, from the FDA to market the first laser system designed to treat heart disease.
 -0- 4/15/92
 /CONTACT: Connie McCluskey of Advanced Interventional Systems, 714-586-1342, or at the ACC: Booth No. 1328, or the Loews Anatole Hotel, 214-748-1200/
 (LAIS) CO: Advanced Interventional Systems ST: California, Texas IN: MTC SU:


CH-AL -- LA019 -- 8677 04/15/92 12:05 EDT
COPYRIGHT 1992 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1992 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Apr 15, 1992
Words:491
Previous Article:SNO COUNTRY REPORTS OFFICIAL SKI REPORT FOR APRIL 15, 1992
Next Article:LOJACK ANNOUNCES FIRST LICENSE AGREEMENT FOR NEW CARSEARCH SYSTEM FOR STOLEN VEHICLE RECOVERY


Related Articles
ADVANCED INTERVENTIONAL SYSTEMS ADDS NEW CATHETER TO CLINICAL TRIALS WITH EXCIMER LASER SYSTEM
A laser beam to open up blocked arteries.
Spectranetics Corporation Announces Clinical Evaluations of Device That Treats Totally Blocked Coronary Arteries
Spectranetics Corporation Receives Approval in Europe for Excimer Laser Treatment of Restenosed Stents
Spectranetics Announces CE Mark Approval for the Vitesse COS Coronary Laser Catheter.
Spectranetics Receives Approval to Market its Largest Laser Coronary Angioplasty Catheter for Use in Europe.
Spectranetics Receives CE Mark in Europe to Market New Laser Catheter For Coronary Angioplasty Designed to Treat Small Vessels.
Spectranetics Receives FDA Approval to Market Vitesse 0.9 MM Catheter.
Article Published in American Journal of Cardiology Demonstrates Safety And Effectiveness of Excimer Laser Coronary Angioplasty To Treat Patients...
Medical Journal Article Suggests Excimer Laser Energy Inhibits Ability Of Platelets to Aggregate Into Blood Clots.

Terms of use | Copyright © 2017 Farlex, Inc. | Feedback | For webmasters